* For research use only, not for use in diagnostic procedures.
The CDIATM Creatine Kinase MB Immunofluorescence Test Cassette is designed for quantitative determination of creatine kinase MB in human serum, whole blood or plasma.
The test uses an anti-human CK-MB monoclonal antibody conjugated with fluorescence latex and another anti-human CK-MB monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human CK-MB monoclonal antibody binds with the CK-MB in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human CK-MB monoclonal antibody. The fluorescence intensity of the test line increases in proportion to the amount of CK-MB in sample. Then insert test card into the Fluorescent Immunoassay Analyzer FIA7100, the concentration of CK-MB in sample will be determined and displayed on the screen.
Creatine kinase is a dimer existing in three isoenzymic forms, depending on the particular combination of its subunits: BB(brain type);MM(skeletal type); and MB(hybrid type). Creatine kinase-MB isoenzyme is released into circulation later than myoglubin, reaching abnormal levels within 4 to 6 hours after onset of symptoms. It reaches its highest level after about 18 to 24 hours, and returns to normal in about 2 to 3 days. CK-MB is widely recognized as the traditional marker for the diagnosis of acute myocardial infarction (AMI). This kit is intended to use in quantitative detection of CK-MB content in human serum, plasma or whole blood.